Scientists aware of faulty protein can harmful deposits in neurological disorders such as Alzheimer’s and Parkinson’s disease. The cause of the deposition of the proteins remains puzzled and known that abnormal aggregates can result when cells fail to transmit proper genetic information to proteins.
Professor Susan Ackerman and her colleagues from The University of California San Diego had first high highlighted this cause of brain disease more than 10 years ago.
Now, they identified a gene, Ankrd16, that may be able to stop the accumulation of protein deposits in the brain, a factor in developing brain diseases like Alzheimer’s and Parkinson’s disease.
It’s long been believed that protein deposits in the brain cause a series of events that lead to dementia. However, there is no test to determine if someone has dementia or the leading type of dementia, Alzheimer’s disease.
The information transfer from gene to protein is carefully controlled — biologically “proofread” and corrected — to avoid the production of improper proteins. Proofreading is the process of cells correcting mutations.
As part of their recent investigations, published in the journal Nature, Ackerman, Paul Schimmel (Scripps Research Institute) My-Nuong Vo (Scripps Research Institute) and Markus Terrey (UC San Diego) identified that Ankrd16 rescued specific neurons — called Purkinje cells — that die when proofreading fails.
Without normal levels of Ankrd16, these nerve cells, located in the cerebellum, incorrectly activate the amino acid serine, which is then improperly incorporated into proteins and causes protein aggregation.
“Simplified, you may think of Ankrd16 as acting like a sponge or a ‘failsafe’ that captures incorrectly activated serine and prevents this amino acid from being improperly incorporated into proteins, which is particularly helpful when the ability of nerve cells to proofread and correct mistakes declines,” said Ackerman, the Stephen W. Kuffler Chair in Biology, who also holds positions in the UC San Diego School of Medicine and the Howard Hughes Medical Institute.
The levels of Ankrd16 are normally low in Purkinje cells, making these neurons vulnerable to proofreading defects. Elevating the level of Ankrd16 protects these cells from dying while removing Ankrd16 from other neurons in mice with a proofreading deficiency caused widespread buildup of abnormal proteins and ultimately neuronal death.
The researchers describe Ankrd16 as .” ..a new layer of the machinery essential for preventing severe pathologies that arise from defects in proofreading.”
The researchers note that only a few modifier genes of disease mutations such as Ankrd16 have been identified and a modifier-based mechanism for understanding the underlying pathology of neurodegenerative diseases may be a promising route to understand disease development.
Source: ScienceDaily. Read the original post.